Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon May 16, 2024 3:24pm
212 Views
Post# 36044075

Well, well …

Well, well …

It would seem that we have ended the option/rsu/psu grant phase and the last (?) round of financing phase before completion of Trial in 6 to 9 months. 

I agree that the terms of the last financing was about the best we could hope for in terms of minimizing the amount of further dilution. 

What happens in the next phase ?  While if 2016 is any indication - it's when the market begins to anticipate a successful completion of the Trial. I call it the run up to results phase. It's the reason that the ability to buy shares at 40 cents ( and slightly below that ) just two months ago was a gift ! 

Those newbies that may be drawn in and that start to kick the tires will reference Paradigms math and equally do some math using Spectral's EBITDA blue sky estimates on 2025 and beyond (projected sales and profits). 

Holders would be well advised to review EBITDA multiples for US based medical technology and device companies 

All good !!

The next 6 months or so should be fun ! 


MM 

<< Previous
Bullboard Posts
Next >>